Transcranial direct current stimulation (tDCS) in anorexia nervosa and bulimia nervosa
ISRCTN | ISRCTN70396934 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN70396934 |
Secondary identifying numbers | N/A |
- Submission date
- 05/03/2014
- Registration date
- 29/04/2014
- Last edited
- 06/10/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Plain English summary of protocol
Background and study aims
Psychological therapies are often not effective for people with eating disorders such as anorexia nervosa (AN) and bulimia nervosa (BN), so there is a need for new treatments. Research shows that the frontal areas of the brain play an important role in the development and maintenance of these disorders. Stimulating these brain areas to alter their functioning could possibly reduce the symptoms. A technique that is capable of stimulating specific brain areas is called transcranial direct current stimulation (tDCS). This procedure involves the delivery of a low electrical current via small electrodes places on the scalp, and is widely used in research. This study aims to find out the short-term effects of a single session of tDCS in people who suffer from AN or BN. In particular, we are interested in its effects on thought processes and emotions relating to food, eating, weight and body shape. In the long term, this may help us to develop improved treatments for eating disorders.
Who can participate?
We will be recruiting 36 people with a diagnosis of AN and 36 people with a diagnosis of BN. Participants can be male or female but must be over 18 years old.
What does the study involve?
Participants will come to the lab for three tDCS sessions with a gap of at least 48 hours between each one. Two of these sessions will be real and one will be a placebo (fake) session. On each day participants will complete a series of questionnaires and computer tasks before and after the stimulation session.
What are the possible benefits and risks of participating?
Although there are no direct benefits associated with taking part in this study, the information we get may help us to improve the treatment of eating disorders in the future. There are no known risks involved in taking part in this study, but participants may find the procedure slightly uncomfortable. Most people report feeling a mild tingling sensation during tDCS.
Where is the study run from?
The study will take place at the Institute of Psychiatry, Kings College London, UK.
When is the study starting and how long is it expected to run for?
The testing is expected to begin in April 2014 and continue until we have recruited and tested 72 participants (about 2 years).
Who is funding the study?
The study is being funded by the Institute of Psychiatry, Kings College London, UK.
Who is the main contact?
Ms Maria Kekic
Email: maria.kekic@kcl.ac.uk
Tel: 02078480183
Contact information
Scientific
Section of Eating Disorders
Department of Psychological Medicine
Institute of Psychiatry, P059
King's College London
16 De Crespigny Park
London
SE5 8AF
United Kingdom
Phone | 02078480183 |
---|---|
maria.kekic@kcl.ac.uk |
Study information
Study design | Single-centre randomised double-blind placebo-controlled crossover study |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Other |
Study type | Treatment |
Participant information sheet | Anorexia nervosa: http://www.pdf.investintech.com/preview/1f56ce4c-a44f-11e3-a493-002590d31986/index.htmlBulimia nervosa: http://www.pdf.investintech.com/preview/c6fa6e54-a451-11e3-a493-002590d31986/index.html |
Scientific title | An experimental sham-controlled crossover study of prefrontal cortex transcranial direct current stimulation (tDCS) in patients with anorexia nervosa and bulimia nervosa |
Study acronym | TREAT |
Study objectives | We aim to establish whether a single session of prefrontal tDCS can temporarily reduce eating disorder symptoms, improve mood, and alter cognitive functioning in patients with anorexia nervosa and bulimia nervosa. |
Ethics approval(s) | City Road and Hampstead National Research Ethics Service (NRES) committee;10/02/2014; ref: 14/LO/0025 |
Health condition(s) or problem(s) studied | Anorexia nervosa and bulimia nervosa |
Intervention | This study has three interventions: 1. Anode right/cathode left tDCS (active) 2. Anode left/cathode right tDCS (active) 3. Placebo tDCS All participants will receive all three interventions (the order of stimulation will be randomised and counterbalanced across participants). A minimum 48-hour interval will be used between sessions to avoid any carryover effects due to stimulation. Each session will be 20 minutes long. Active tDCS will be delivered using a neuroConn® DC-STIMULATOR device at a constant current of 2 mA (with a 10-second fade in/out) using two 4 cm2 surface sponge electrodes soaked in a sterile saline solution (0.9% sodium chloride). The anode and cathode will be placed over the right (F4) and left (F3) dorsolateral prefrontal cortex (DLPFC), respectively, for intervention 1, and vice versa for intervention 2. The sites of interest will be located using the International EEG 10-20 system. For placebo tDCS, the electrodes will be placed at the same sites as in active tDCS but the stimulation will automatically turn off after 30 seconds. Participants will therefore experience the initial itching sensation but will receive no current for the rest of the 20-minute session. |
Intervention type | Other |
Primary outcome measure | The visual analogue scale (VAS) scores (0-10) obtained post-tDCS relating to hunger, urge to eat, urge to binge, urge to purge, urge to exercise, urge to restrict, feeling fat, and feeling full. |
Secondary outcome measures | 1. Post-tDCS VAS scores (0-10) relating to food ratings, stress, anxiety, tension, and mood. 2. Post-tDCS Mizes Eating Disorder Cognitions Questionnaire-Revised (MEDCQ-R) scores 3. Post-tDCS Profile of Mood States (POMS) scores 4. Post-tDCS delay discounting scores 5. Eating disorder symptoms (measured using VAS) at 24-hour follow-up 6. Blinding success 7. Tolerability of the intervention |
Overall study start date | 01/04/2014 |
Completion date | 30/09/2016 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 72 |
Total final enrolment | 39 |
Key inclusion criteria | 1. Male or female 2. Aged over 18 3. Current DSM-V diagnosis of either: 3.1. Anorexia nervosa-restricting type 3.2. Anorexia nervosa-binge/purge type 3.3. Eating disorder not otherwise specified-anorexia type 3.4. Bulimia nervosa 3.5. Eating disorder not otherwise specified-bulimia type |
Key exclusion criteria | 1. Having a history of head or eye injury 2. Having a history of a neurological disease including previous seizures of any kind 3. Having a history of frequent or severe headaches 4. Having metallic implants in the head 5. Being on a dose of any psychotropic medication that has not been stable for at least 14 days prior to participation in the study 6. Taking antipsychotic medication 7. Taking anticonvulsive medication 8. Being pregnant 9. Smoking more than 15 cigarettes per day 10. Having a current major psychiatric disorder other than the eating disorder (e.g. major depressive disorder, substance use disorder, schizophrenia, or bipolar disorder) needing treatment in its own right 11. Having severe abnormalities in a blood test during the 30 days prior to participation |
Date of first enrolment | 01/04/2014 |
Date of final enrolment | 30/09/2016 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
SE5 8AF
United Kingdom
Sponsor information
University/education
C/O Keith Brennan
Room 1.8 Hodgkin Building
Guy's Campus
London
SE1 4UL
England
United Kingdom
https://ror.org/0220mzb33 |
Funders
Funder type
University/education
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 25/01/2017 | 06/10/2020 | Yes | No |
HRA research summary | 28/06/2023 | No | No |
Editorial Notes
06/10/2020: The following changes have been made:
1. Publication reference added.
2. The final enrolment number has been added from the reference.